India's homegrown Covid-19 vaccine, Covaxin, has been declared "safe and immunogenic with no serious side effects" by Lancet that has published its phase 2 results.
Lancet has said that efficacy cannot be determined by phase 2 trials but the vaccine made by Hyderabad-based Bharat Biotech is "safe/immunogenic".
Covaxin was authorized for use in January before full clinical trial data leading to some concerns about its safety.
Bharat Biotech had last week said that interim analysis of Phase 3 of its trial showed Covaxin is 81% effective in protecting against Covid-19.
Also Read: PM Modi gets first dose of Covid-19 vaccine. Tweets pic & appeal
Farmers to clear one side of Singhu border for oxygen supplies
Covid+ Delhi lawmaker sends oxygen shortage alarm from Delhi hospital bed
EC puts cap on Bengal campaigning as Kolkata HC seeks report
Covid-19: UAE to stop flights between Dubai and India for 10 days from April 25
Ruckus at Attari border: 200 pilgrims test Covid+ after returning from Pakistan
India's top doctors' address on COVID crisis
Poonawalla a 'dacoit', Centre must take over SII: BJP lawmaker
Your illegal migrant vote bank real outsiders: Shah attacks Mamata
Watch: militants clad in PPE kits loot bank in Kashmir
PM says he won't hold Bengal rally, will chair Covid-19 meetings
Uttar Pradesh records highest-ever daily spike in Covid-19 cases
Give full Oxygen quota to Delhi, ensure tanker safety: HC to Centre
Former Delhi minister AK Walia succumbs to Covid-19
States must act against hoarding: PM Modi chairs meet on oxygen shortage
Covid-19 resurgence: Australia to reduce flights from India
EC-dismisses TMC allegations of firing by central forces
Over 300 passengers flee Silchar airport to avoid Covid testing after creating ruckus
Mumbai Police's cracker of a reply to man missing girlfriend in lockdown
Covid spike: Centre issues fresh directive for Oxygen supply